Previous Close | 34.73 |
Open | 34.92 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 34.49 - 35.40 |
52 Week Range | 6.40 - 47.45 |
Volume | |
Avg. Volume | 1,262,581 |
Market Cap | 3.538B |
Beta (5Y Monthly) | 1.05 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.58 |
Earnings Date | Oct 28, 2024 - Nov 01, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 54.11 |
- Presentations Will Feature Recent Clinical Data From DYNE-251 and DYNE-101 as Well as Preclinical Data in FSHD and Pompe Disease - WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that previously reported clinical and preclinical data across its pipeline will be featured in poster prese
We recently compiled a list of the 10 Best Hot Stocks To Buy Right Now. In this article, we are going to take a look at where Dyne Therapeutics, Inc. (NASDAQ:DYN) stands against the other hot stocks. While the market is seeing significant positives after the Fed rate cut, there have been some pressures. For example, […]